[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Rochester\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":612},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,110,0,25,[9,42,62,91,117,142,166,187,212,240,260,283,305,328,352,375,399,425,443,465,491,515,539,561,588],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634672","phase-4-diphenhydramine-as-an-adjunct-to-moderate-sedation-for-procedural-first-trimester-abortions-100634672",false,"NCT07542730","Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions","Inclusion Criteria:\n\n* Adults age 18 years and older\n* Desire procedural abortion with moderate sedation\n* Gestational age less than or equal to 13 weeks\n* Intrauterine pregnancy or pregnancy of unknown location\n* Body mass index less than or equal to 40\n\nExclusion Criteria:\n\n* Desire medical abortion or desire to continue pregnancy\n* Gestational age greater than 13 weeks\n* Body mass index greater than 40\n* Age younger than 18 years\n* Confirmed ectopic pregnancy\n* Medical condition that is a contraindication to moderate sedation as determined by the treating clinician","FEMALE","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This single center, double blind, randomized controlled trial will evaluate whether adding intravenous diphenhydramine to a standard moderate sedation regimen improves pain control during first trimester procedural abortion. Participants undergoing uterine aspiration at less than 13 weeks gestation will be randomized 1 to 1 to receive standard moderate sedation with midazolam and fentanyl plus either diphenhydramine 50 mg intravenously or matching placebo. The primary outcome is participant reported pain during uterine aspiration measured by a 100 mm Visual Analog Scale.",[26,27,28],"Pain","Abortion","Anxiety","RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":33},"2026-06-29",{"date":37,"type":20},"2027-02",{"name":39,"class":40},"University of Rochester","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":48,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100477415","meningitis-burden-causes-screening-and-prevention-in-rural-northern-uganda-100477415","NCT05496673","Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda","Inclusion Criteria:\n\n* 1100 patients who present with meningitis or meningitis symptoms, regardless of age or vulnerably status are eligible for meningitis testing.\n* 10,000 HIV-infected patients presenting to LRRH, LRRH HIV Clinic (LIDC) or nearby outpatient clinics, regardless of age or vulnerability status, are eligible for CrAg screening.\n\nExclusion Criteria:\n\n* Patients who are found not to have meningitis after initial evaluation, or are found to have other alternative diagnoses that explain their symptoms, will be excluded.\n* HIV-negative patients without signs or symptoms of meningitis.","ALL",{"count":50,"type":20},11100,[52],"NA","This study will investigate the burden, causes, diagnostics, treatments and preventive measures related to meningitis in northern Uganda. We hypothesize that understanding the burden of meningitis, risk factors, diagnostics, treatments and the preventive measures will provide information regarding the gaps in care that can be addressed in order to improve the continuum of meningitis care. we hypothesize that our data will support the advocacy for the implementation of routine vaccination for the prevention of bacterial meningitis and improving guidelines for Cryptococcal antigen (CrAg) screening for prevention of cryptococcal meningitis, which will save lives in Uganda.\n\nAim 1: To prospectively collect data on 1100 patients with meningitis and meningitis symptoms who were admitted to Lira Regional Referral Hospital (LRRH) to assess burden, etiologies, pathogenesis, and outcomes of meningitis using modern diagnostic testing not previously available in Uganda.\n\nAim 2: To perform CrAg screening of 10,000 HIV-positive patients to determine the prevalence of cryptococcal antigenemia (infection) and conduct a case control study to compare risk factors and outcomes among CrAg-positive patients and matched CrAg-negative controls based on age, sex, TB status, ART experience, CD4 count, and viral load.",[55],"Meningitis",{"date":32,"type":33},{"date":58,"type":33},"2022-09-01",{"date":60,"type":20},"2031-09-01",{"name":39,"class":40},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100612998","investigating-the-effects-of-repetitive-transcranial-magnetic-stimulation-rtms-on-the-brain-in-people-with-fibromyalgia-100612998","NCT07260864","Investigating the Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on the Brain in People With Fibromyalgia","Investigating the Differential Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Left and Right Motor Cortex in Fibromyalgia: A Prospective Randomized Trial With Functional Magnetic Resonance Imaging (MRI(","rTMS","Inclusion Criteria:\n\n* Female aged 18 to 65, right-handed, with no racial\u002Fethnic restrictions.\n* A diagnosis of fibromyalgia by a qualified physician according to the American College of Rheumatology 2016 criteria\n* Must have a history of fibromyalgia pain for a duration ≥ 3 months, as it is included in the diagnostic criteria.\n* Must have pain intensity equal or greater than 4\u002F10 on the numerical rating scale (NRS) at enrollment.\n* Concurrent chronic overlapping pain conditions (except migraine with aura), depression, and anxiety will be allowed when mild to moderate (Less than 31 on Beck Depression Inventory or less than 36 on Beck Anxiety Inventory), except in cases with psychotic or manic features.\n* Concomitant medication (except tricyclics, antipsychotic medications, bupropion, methadone, theophylline) and their doses for mood, pain and sleep disorders must be steady at least 4 weeks before enrolment and must be kept at a steady dosage during the trial.\n* Must be able to read and speak English and be willing to read and understand instructions as well as questionnaires.\n* Must be in generally stable health.\n* Must sign an informed consent document after explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Age outside the studied range (i.e., \\\u003C 18, \\> 65).\n* Patients planning to change their medications during trial.\n* Participants who are currently receiving other alternative therapies during trial (e.g., physiotherapy, acupuncture).\n* History of receiving TMS, transcranial direct current stimulation (tDCS), or electroconvulsive therapy (ECT).\n* Evidence of rheumatologic disorders, autoimmune diseases, taking immunosuppressive treatment, severe or unstable cardiac diseases.\n* Fibromyalgia must be the primary complaint; hence patients cannot have another main source of pain (e.g., osteoarthritis). Patients will be asked to shade all the areas in which they experience pain on a body map. If they shade areas other than typical fibromyalgia pain, we will discuss any previous diagnosis, the intensity and chronicity of pain, and exclude them if chronic pain in any area outside the condition in to be studied is confirmed.\n* Involvement in litigation regarding their pain or having a disability claim or receiving workman compensation or seeking either because of their pain.\n* Any history of hemorrhagic or thrombotic stroke.\n* History of schizophrenia, schizoaffective disorder, bipolar disorders, mania, hypomania, eating disorders, or any psychiatric illness with psychotic features (major depressive disorder, mild to moderate without psychosis, or anxiety disorders are not exclusion criteria).\n* Current use of tricyclic antidepressants or any antipsychotic medications, given the risk of seizure incidence independent of TMS use in tricyclics is up to 0.4% or second-generation antipsychotics up to 1.2%.\n* Significant other medical disease such as unstable diabetes mellitus, congestive heart failure, coronary or peripheral vascular disease, chronic obstructive lung disease, sleep apnea, or malignancy. Stable diabetes mellitus, stable hypertension (meaning that these conditions are followed up on by a physician and they are getting treatment for it with clinical stability), or hyperlipidemia are not exclusion criteria.\n* History of traumatic brain injury\n* History of epileptic disorders or family history of seizures in first degree relatives\n* History of syncope\n* History of tinnitus or hearing loss\n* Current or history of substance misuse\u002Fdependence including alcohol at time of entry into the study.\n* History of COVID-19 infection with persistent neurologic symptoms.\n* Intra-axial implants (e.g., spinal cord stimulators or pumps) that are MRI incompatible.\n* All exclusion criteria for MRI and TMS safety: any metallic implants, chips, or plates, cochlear implants, brain or skull abnormalities, aneurysm clips or coils, non-removable piercings, tattoos containing ferromagnetic ink, and claustrophobia.\n* Surgery within the past 3 months or history of any brain surgery\n* Pregnancy\n* Participation into another research study\n* In the judgment of the investigator, unable or unwilling to follow the protocol and instructions.","65 Years",{"count":72,"type":20},20,[52],"The first goal of this study is to see how brain activity changes in people with fibromyalgia after they get a treatment called rTMS (repetitive transcranial magnetic stimulation). Researchers are looking at how the parts of the brain that control movement (called motor cortices) respond to this treatment.\n\nThe second goal is to find out if the changes in brain activity are different between the right and left sides of the brain, depending on which side gets the treatment.",[76],"Fibromyalgia (FM)",[78,79,80,81,82],"Transcranial Magnetic Stimulation","Chronic Pain","Nociplastic pain","Functional Magnetic Resonance Imaging","Motor Cortex","2026-08-18",{"date":85,"type":33},"2026-08-20",{"date":87,"type":33},"2025-12-05",{"date":89,"type":20},"2027-01",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100606703","phase-2-a-phase-2-study-of-methylene-blue-photodynamic-therapy-for-treatment-of-breast-abscesses-100606703","NCT07179003","A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses","Inclusion Criteria:\n\n* Adults 18 years or older\n* Clinical signs of breast abscess, including pain, redness, and\u002For heat of the breast\n* Approval by the primary care team to pursue PDT and discuss enrollment with the patient\n\nExclusion Criteria:\n\n* Pregnancy\n* Lactation\n* Allergy to contrast media, narcotics, sedatives, atropine or eggs\n* Necrotic tissue that requires surgical debridement\n* Severely compromised cardiopulmonary function or hemodynamic instability\n* Thrombocytopenia (\\\u003C50,000\u002Fmm3)\n* Uncorrectable coagulopathy\n* Poor kidney function (serum creatinine \\>3mg\u002Fdl)\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Patients with hidradenitis suppurativa\n* Patients with granulomatous mastitis\n* Unable or unwilling to understand or to provide informed consent\n* Unable or unwilling to undergo study procedures\n* Patient unable to cooperate with, or to be positioned for the procedure\n* Unable to comply with necessary follow up",{"count":98,"type":20},50,[100],"PHASE2","The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. The investigators hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.",[103],"Breast Abscess",[105,106,107,108],"Breast abscess","Drainage","Photodynamic therapy","Methylene blue","NOT_YET_RECRUITING","2026-08-17",{"date":30,"type":33},{"date":113,"type":20},"2027-07",{"date":115,"type":20},"2032-06",{"name":39,"class":40},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":124,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100600057","the-baby-duchenne-study-characterizing-developmental-and-clinical-outcomes-in-the-first-three-years-in-children-with-duchenne-muscular-dystrophy-100600057","NCT07092540","The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy","BABY DUCHENNE","Inclusion Criteria:\n\n* Male child between birth and 3.0 years of age at time of enrollment.\n* A confirmed and documented pathogenic or likely pathogenic variant in the DMD gene.\n* Ability of parent\u002Fguardian to understand and provide written informed consent (signing Parental Permission and Consent Form).\n* Willingness of parent\u002Fguardian to comply with the protocol Schedule of Activities, including all study site visits.\n\nExclusion Criteria:\n\n* Female\n* Presence of any confirmed genetic disease, other than DMD, that could impact early development, which, in the opinion of the PI, may confound interpretation of developmental progress.\n* Presence of any significant medical condition (i.e., extreme prematurity, hypoxic ischemic encephalopathy) which, in the opinion of the PI, may confound interpretation of the clinical course of DMD.\n* Inability\u002Funwillingness of parent\u002Fguardian to provide written permission (sign PPF) or to comply with the protocol Schedule of Activities.","MALE","0 Days","3 Years",{"count":128,"type":20},105,"OBSERVATIONAL","The aim of the BABY DUCHENNE study is to evaluate the natural history and characterize the early clinical outcomes in very young children (0-3 years) with Duchenne muscular dystrophy (DMD) identified by newborn screening programs.",[132],"Duchenne Muscular Dystrophy (DMD)",[134],"New born screening",{"date":30,"type":33},{"date":137,"type":33},"2026-06-03",{"date":139,"type":20},"2029-08-31",{"name":39,"class":40},4,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":48,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100652495","two-photon-fluorescence-microscopy-of-dermatologic-biopsies-100652495","NCT07773688","Two-photon Fluorescence Microscopy of Dermatologic Biopsies","Expanded Two-photon Imaging of Skin Biopsy Specimens","Inclusion Criteria:\n\n* Punch, excisional or shave biopsy specimen\n\nExclusion Criteria:\n\n* Biopsies composed of multiple excisions or pieces",{"count":150,"type":20},644,[52],"The goal of this study is to investigate the ability of two-photon fluorescence microscopy to evaluate dermatologic biopsies. The main questions it aims to answer are:\n\n• How well do two-photon fluorescence images of biopsies taken in a clinic and evaluated by a pathologist agree with conventional histology?",[154,155,156],"Basal Cell Carcinoma of Skin","Squamous Cell Carcinoma","Melanocytic Lesion, Adult",[158],"two-photon microscopy","2026-08-15",{"date":30,"type":33},{"date":162,"type":33},"2026-06-01",{"date":164,"type":20},"2028-04",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":48,"minAge":4,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":41},"100646991","machine-learning-analysis-of-two-photon-fluorescence-microscopy-of-dermatologic-biopsies-100646991","NCT07682831","Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies","Machine Learning Analysis of Expanded Two-photon Imaging of Skin Biopsy Specimens","Inclusion Criteria:\n\n* Punch, excisional or shave biopsy specimen\n\nExclusion Criteria:\n\n* Biopsy indication includes melanoma or dysplastic\u002Fatypical nevus\n* Excision thickness of less than 1 mm\n* Excision longest dimension less than 2 mm\n* Excision performed as multiple pieces in a single specimen container",{"count":174,"type":20},92,[52],"The goal of this study is to investigate the ability of a machine learning model to evaluate two-photon fluorescence microscopy images of dermatologic biopsies at point of care.\n\nThe main question it aims to answer is:\n\n• How well do two-photon fluorescence images of biopsies taken in a clinic and evaluated by a machine learning model agree with conventional histology?",[154,178],"Squamous Cell Carcinoma (Skin)",[158,180],"machine learning",{"date":30,"type":33},{"date":183,"type":33},"2026-06-24",{"date":185,"type":20},"2027-07-01",{"name":39,"class":40},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":41},"100633643","feasibility-of-exercise-for-cancer-patients-and-healthy-eating-timeframes--100633643","NCT07529353","Feasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' .","Feasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' (EXCAP-hEAT) Among Breast Cancer Survivors Receiving Adjuvant Endocrine Therapy.","EXCAP-hEAT","Inclusion Criteria:\n\n* Must be aged 18 years or older\n* Must have a confirmed diagnosis of breast cancer (stage I-IIIC)\n* Must have completed adjuvant chemotherapy, surgery, and\u002For radiation for cancer at least 2 - 120 months prior to enrolling,\n* Must be prescribed adjuvant endocrine therapy,\n* Must have a baseline level of fatigue, as determined by reporting a score of 4 or higher on the Symptom Inventory\n* Must have a body mass index greater than or equal to 25 kg per meter squared\n* Must have the ability to ambulate independently\n* Must be willing and able to participate in home-based exercise and eating timeframe intervention\n* Must have the ability to read and understand the English language,\n\nExclusion Criteria:\n\n* Must not have metastatic or recurrent breast cancer\n* Must not be currently receiving chemotherapy or radiation therapy\n* Must not have a medical condition that would preclude safe participation in intervention or study procedures\n* Must not be pregnant, or planning to become pregnant during the study period\n* Must not be in the active or maintenance stage of exercise behavior as assessed by the Exercise Stages of Change Short Form,\n* Must not have any condition that in the opinion of the investigator would interfere with participation or safety\n* Must not be currently using, or plan to initiate use of prescription or over-the-counter weight-loss medications",{"count":72,"type":20},[52],"This study evaluates the feasibility and preliminary effects of a home based exercise and activity program for individuals with cancer. Participants will engage in a structured intervention designed to support physical activity and symptom management. The study will assess changes in patient reported outcomes, functional measures, and overall adherence to the program. Findings will help determine whether this approach is practical and potentially beneficial for improving health related outcomes in this population.",[199,200],"Breast Cancer","Cancer Related Fatigue",[202,203,204],"Breast Cancer Survivorship","Home Based Exercise","Fatigue Management","2026-08-13",{"date":110,"type":33},{"date":208,"type":20},"2026-10",{"date":210,"type":20},"2028-10",{"name":39,"class":40},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":48,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":229,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":41},"100630506","engage-coaching-r33-phase-100630506","NCT07488559","Engage Coaching (R33 Phase)","Engage Coaching to Reduce Social Isolation and Loneliness to Prevent Suicide in Later Life","Inclusion criteria:\n\n* Age 60 or older\n* Access to social activities outside the home, including through living in senior living communities\n* Clinically-significant loneliness over the prior month.\n\nExclusion criteria:\n\n* Current problem drinking\n* Psychosis\n* Significant cognitive impairment\n* Hearing problems that preclude engagement with S-ENG and research assessors.","60 Years",{"count":221,"type":20},120,[52],"The purpose of this study is to test whether an individual coaching program helps adults age 60 and older feel more connected to other people in ways that matter to them.",[225,226,227,228],"Social Connection","Loneliness","Suicide Ideation","Social-emotional Quality of Life",[226,230,231,232,233],"Older adults","Ecological momentary assessment","Engage Psychotherapy","Late-life suicide",{"date":110,"type":33},{"date":236,"type":33},"2026-06-30",{"date":238,"type":20},"2028-12-31",{"name":39,"class":40},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":41},"100626061","briter-eyez-moisture-vue-on-demand-disposable-moisture-chamber-100626061","NCT07430735","BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber","A Clinical Evaluation of the BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber in Subjects With Mild to Moderate Dry Eye Disease","Inclusion Criteria:\n\n* 18 years of age or older\n* Clinical Diagnosis of mild to moderate dry eye\n* Individual wears eyeglass spectacles\n\nExclusion Criteria:\n\n* Children under the age of 18 years of age\n* Women who are currently pregnant or nursing\n* Adults with decisional impairment\n* Prisoners\n* Individuals who have a known ocular or medical condition (other than DED) that impacts their ocular surface and could confound the results of the study.",{"count":248,"type":20},35,[52],"The purpose of this study is to evaluate the short-term effects (impact on tear film and dry eye symptoms) of the BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber (the device under investigation) in individuals with mild to moderate dry eye disease. Specifically, the study aims to determine whether wearing the device for two hours improves tear-film stability, tear volume, and tear osmolarity,",[252],"Dry Eye Disease (DED)",[254],"Dry Eye",{"date":110,"type":33},{"date":257,"type":20},"2026-08-31",{"date":185,"type":20},{"name":39,"class":40},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":268,"sex":48,"minAge":269,"maxAge":70,"enrollmentInfo":270,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":41},"100593766","digital-measures-for-clinical-trial-endpoints-in-huntingtons-disease-100593766","NCT07010705","Digital Measures for Clinical Trial Endpoints in Huntington's Disease","Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)","MEND-HD","Inclusion Criteria:\n\nInclusion Criteria for participants with adult-onset HD:\n\n* Age of 25-65 years.\n* Genetically confirmed HD with CAG \\>= 40 (HD-ISS Stage 2 or mild\u002Fmoderate Stage 3)\n* English speaking.\n\nInclusion Criteria for control participants:\n\n* Age of 25-65 years.\n* English speaking.\n\nInclusion Criteria for support persons:\n\n* Self-identified support person or family member of the enrolled participants with HD.\n* 18 years or older\n* English speaking.\n\nExclusion Criteria:\n\n* Diagnosis of juvenile-onset HD.\n* History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe\n* Traumatic Brain Injury.\n* Use of an assistive device for ambulation.\n* Montreal Cognitive Assessment (MoCA) score of 18 or lower\n* Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,\n* cardiovascular or psychiatric disease.\n* Pregnancy\n* Cannot be enrolled into a blinded intervention trial at Baseline",true,"25 Years",{"count":271,"type":20},100,"MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners\u002Fsupport persons.\n\nParticipants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives.\n\nParticipant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.\n\nThe study may be extended to 3 years to include yearly visits.",[274,275],"Huntington Disease","Healthy",[274],{"date":110,"type":33},{"date":279,"type":33},"2025-06-20",{"date":281,"type":20},"2027-11-30",{"name":39,"class":40},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":268,"sex":48,"minAge":289,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":41},"100649562","the-villainous-vape-advancing-vaping-prevention-among-adolescents-through-a-comic-book-100649562","NCT07737080","The Villainous Vape: Advancing Vaping Prevention Among Adolescents Through a Comic Book","Inclusion Criteria:\n\n* Know how to read and speak English and\u002For Spanish\n* Be at least 12 but no greater than 17 years old\n* Be willing to complete three study visits over Zoom or a phone call\n* Live in Orleans County, New York\n\nExclusion Criteria:\n\n* A household member participating in the study\n* Living outside of Orleans County, New York","12 Years","17 Years",{"count":292,"type":20},90,[52],"This is a randomized controlled trial to assess the feasibility, acceptability, and preliminary impact of The Villainous Vape, a vaping prevention comic book, among adolescents.",[296],"Vaping Behaviors","2026-07-27",{"date":299,"type":33},"2026-07-30",{"date":301,"type":20},"2026-09-01",{"date":303,"type":20},"2027-03-31",{"name":39,"class":40},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":48,"minAge":125,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":41},"100609575","phase-2-caffeine-optimization-for-oxygen-saturation-index-in-elbw-infants-100609575","NCT07216365","Caffeine Optimization for Oxygen Saturation Index in ELBW Infants","Caffeine Optimization for Oxygen Saturation Index in ELBW Infants (COFIE Trial)","COFIE trail","Inclusion Criteria:\n\n* URMC Inborn Newborn infants born with gestational age of 22 weeks 0 days - 27 weeks 6 days or infants OR ≥ 28 weeks with a birthweight \\\u003C 1000 grams\n\nExclusion Criteria:\n\n* Hepatic failure, spontaneous intestinal perforation, necrotizing enterocolitis, Anticipated major congenital or genetic anomalies, infants not anticipated to survive beyond 72 hours, infants with mothers that are non-English speaking or \\\u003C18 years old at time of enrollment.","27 Weeks",{"count":315,"type":20},40,[100],"The goal of this clinical trial is to determine whether a higher dose of caffeine citrate can improve breathing and reduce health complications in extremely premature infants, specifically those born before 28 weeks of pregnancy, known as ELGAN infants. These babies often struggle with breathing due to underdeveloped lungs, and caffeine is commonly used to help support their respiratory function. However, the most effective and safest dose has not yet been clearly established.\n\nThe study aims to answer two main questions: Does a higher maintenance dose of caffeine (10 mg\u002Fkg) lead to better oxygenation, as measured by the Oxygen Saturation Index (OSI), compared to the standard dose (5 mg\u002Fkg)? And does the higher dose reduce the risk of serious complications such as lung disease, brain injury, or death-without causing more side effects like fast heart rate, high blood pressure, or poor growth?\n\nTo answer these questions, researchers will compare two groups of infants: one receiving the high-dose caffeine treatment and the other receiving the standard dose. This comparison will help determine if the higher dose leads to better outcomes without increased risk.\n\nParticipants will begin caffeine treatment once they have regained their birth weight and are at least seven days old. They will be randomly assigned to receive either the high or standard caffeine dose and will be followed until caffeine is stopped or they are discharged from the hospital. During this time, researchers will monitor each infant's oxygenation levels, need for breathing support, signs of common complications, growth and feeding progress, and any side effects. Before discharge, each infant's motor development will also be assessed using a tool called the Test of Infant Motor Performance (TIMP).\n\nThis study could help define the most effective caffeine dosing strategy for supporting extremely premature infants and improving their short-term health outcomes.",[319,320],"Neonatal Apnea","Infants",{"date":322,"type":33},"2026-07-29",{"date":324,"type":33},"2026-07-15",{"date":326,"type":20},"2029-09-01",{"name":39,"class":40},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":48,"minAge":219,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":41},"100649433","phase-2-geriatric-assessment-guided-treatment-selection-in-older-adults-with-acute-myeloid-leukemia-100649433","NCT07735208","Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia","Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia (The ALIGN-AML Trial)","ALIGN-AML","Inclusion Criteria:\n\n1. Age 60 and above\n2. A diagnosis of de novo, secondary or treatment-related acute myeloid leukemia (AML), other AML equivalent such as myeloid sarcoma, myelodysplastic syndrome in transformation to AML\n\n   1. AML diagnosis can be based on the World Health Organization (WHO) 2022 criteria or International Consensus Classification (ICC) 2022 criteria\n   2. The use of hydroxyurea, cytarabine (up to 1 gm total dose), or leukapheresis for cytoreduction is allowed\n   3. Patients with brief exposure to all-trans retinoic acid (ATRA), arsenic trioxide (ATO) or similar product for suspected acute promyelocytic leukemia (APL), who later turn out not to have APL, are eligible\n   4. The use of other cancer-directed treatments (e.g., hormonal treatment, targeted treatment, immunotherapy, radiation) other than chemotherapy for other concurrent malignancies is allowed\n3. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Acute promyelocytic leukemia\n2. Unwilling to complete study procedures",{"count":221,"type":20},[100],"This is a phase 2 randomized controlled trial to evaluate whether a geriatric assessment (GA)-guided treatment strategy reduces treatment-related toxicity and improves patient-centered outcomes compared with usual oncologist-directed care in adults aged 60 years and older with newly diagnosed AML.",[340],"Acute Myeloid Leukemia",[342,343,344],"AML","Geriatric Assessment","Acute myeloid leukemia","2026-07-24",{"date":322,"type":33},{"date":348,"type":20},"2026-12-01",{"date":350,"type":20},"2031-11-30",{"name":39,"class":40},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":21,"phases":360,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":41},"100636080","the-benefits-of-home-exercise-in-pulmonary-hypertension-interstitial-lung-disease-100636080","NCT07561034","The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease","Inclusion Criteria:\n\n* Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.\n* Adult patients (\\>18 years old) with right heart catheterization confirmed pulmonary hypertension interstitial lung disease on stable therapy dosing for at least 30 days.\n* Access to a smart phone or email to receive daily messages.\n* Clinically stable by the investigator.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Pulmonary Hypertension Groups 1,2,4,5.\n* Resting tachycardia \\>120 beats\u002Fm during screening.\n* Inability to walk.\n* WHO Functional Class IV\n* Lack of access to email or text messaging.\n* Participating in a rehabilitation program.",{"count":359,"type":20},30,[52],"This study evaluates the effects of a structured home exercise program in participants with pulmonary hypertension associated with interstitial lung disease. Participants will complete a defined exercise regimen over a 16-week period, and functional capacity and patient reported outcomes will be assessed at baseline and after the intervention. The study aims to determine whether a home-based exercise approach is feasible and associated with improvements in functional performance.",[363,364],"Pulmonary Hypertension","Interstitial Lung Disease",[366,367,368],"Home Exercise","Exercise Therapy","PH-ILD","2026-07-22",{"date":345,"type":33},{"date":324,"type":33},{"date":373,"type":20},"2027-05-30",{"name":39,"class":40},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":124,"minAge":17,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":41},"100480028","early-phase-1-a-study-to-determine-the-preferred-dose-of-the-drug-lisinopril-for-preventing-urinary-toxicity-following-radiotherapy-for-prostate-cancer-100480028","NCT05530655","A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer","A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer","Inclusion Criteria:\n\n* Have a confirmed diagnosis of adenocarcinoma of the prostate and are candidates for curative-intent external beam radiation (with or without androgen deprivation therapy, ADT) at the Wilmot Cancer Institute Department of Radiation Oncology. Radiotherapy may be either primary, adjuvant or salvage. It may be part of combined treatment with androgen deprivation therapy.\n* Be stage M0 based on the standard of care staging imaging\n* Be able to read English\n* Have the psychological ability and general health that permits completion of the study requirements and required follow up\n* Be ≥18 and \\\u003C 70 years of age\n* Have ECOG performance status of 0 to 2 within 180 days prior to enrollment\n* Have adequate renal function with creatinine clearance \\> 30 mL\u002Fmin within 30 days prior to registration\n* Have hematologic and hepatic function deemed adequate for planned treatment by the treating investigator within 90 days prior to registration, including:\n* hemoglobin ≥9.0 g\u002FdL, independent of transfusion and\u002For growth factors\n* platelet count ≥100,000\u002FµL independent of transfusion and\u002For growth factors\n* Have a baseline systolic blood pressure of \\>130.\n\nExclusion Criteria:\n\n* Have received prior pelvic radiotherapy\n* Be taking lisinopril or other RAS modifying drug within two months prior to registration\n* Have had a prior allergic reaction to lisinopril","70 Years",{"count":359,"type":20},[385],"EARLY_PHASE1","This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.",[388,389,390],"Prostate Cancer","Radiation Toxicity","Urinary Complication","2026-07-21",{"date":393,"type":33},"2026-07-23",{"date":395,"type":33},"2024-02-20",{"date":397,"type":20},"2028-01-01",{"name":39,"class":40},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":268,"sex":16,"minAge":406,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":41},"100536140","expecting-mothers-study-of-consumption-or-avoidance-of-peanut-and-egg-100536140","NCT06260956","Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg","ESCAPE","Inclusion Criteria:\n\n• o Subject must be able to understand and provide informed consent.\n\n* Mothers will be English-speaking adults, 18 years or older. (Spanish speaking adults may be included after consent document is translated and Spanish speaking study representatives are available to conduct and answer questions during informed consent process and for study follow up.)\n* Maternal consent must be provided for infants.\n* Pregnant women from the time pregnancy is confirmed until 27 weeks of gestation.\n* Self-reported at time of enrollment:\n\n  * no chronic inflammatory conditions that require long-term systemic immunosuppressive medications in first or second trimester\n  * carrying a fetus with a first-degree relative (i.e., mother, father, full sibling) with any self-reported or physician-diagnosed allergic disease (asthma, allergic rhinitis, atopic dermatitis, or food allergy).\n* Intend to give their infant their own breast milk for more than 3 months.\n* Can confidently say they have eaten PN and egg and have tolerated consumption with no food allergy reactions.\n* Willing to be randomized to consumption or avoidance diet.\n* Uncomplicated pregnancy (no gestational diabetes, no preeclampsia, no hyperemesis gravidarum), self-reported at time of enrollment.\n\nInfants will be minimum age, 1 day (birth), through 365 days (12 months).\n\nExclusion Criteria:\n\n* Inability or unwillingness of subject to give written informed consent or comply with study protocol.\n* Known history of renal\u002Fliver\u002Fcardiac insufficiency in the mother or infant.\n* Pregnant women with PN or egg allergy.\n* Pregnant women who refuse to eat PN (or peanut products) and\u002For eggs.\n* Physician diagnosed immunodeficiency in the mother or infant.\n* Current, diagnosed, mental illness or current, diagnosed, or self-reported, drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.\n* Past or current medical problems or findings from medical history that are not listed above, which, in the opinion of the investigator, may pose additional risks to the mother or infant from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.","1 Day",{"count":408,"type":20},500,[52],"Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.",[412,413,414,415,416],"Allergy and Immunology","Peanut and Nut Allergy","Egg Allergy","Food Allergy in Infants","Food Allergy Peanut","2026-07-17",{"date":419,"type":33},"2026-07-20",{"date":421,"type":33},"2025-08-01",{"date":423,"type":20},"2029-09",{"name":39,"class":40},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":21,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":41},"100339939","study-comparing-two-different-schedules-of-radiation-for-early-stage-lung-cancer-100339939","NCT03706027","Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer","Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Prospective Randomized Phase II Study","Inclusion Criteria:\n\n* Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified.\n* Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging:\n* T1, N0, M0\n* T2 (≤ 5 cm), N0, M0\n* Patients with hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with \\> 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and\u002For endobronchial US guided biopsy).\n* Zubrod performance status 0-2 within 4 weeks of study entry.\n* Women of childbearing potential and male participants must use an effective contraceptive method.\n* Evaluations required at time of study entry:\n* History \\& Physical by a radiation oncologist within 4 weeks of study entry;\n* Vitals within 4 weeks of study entry;\n* Evaluation by a thoracic surgeon (either via clinical examination and\u002For input at multidisciplinary tumor board) prior to study entry;\n* PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry;\n* CT Chest within 6 weeks of study entry (preferably with intravenous contrast, unless medically contraindicated) - to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on this CT;\n* Whole body positron emission tomography (PET) scan using FDG with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions within 6 weeks prior to study entry.\n* Informed consent signed by the subject and a member of the study team.\n\nExclusion Criteria:\n\n* Patients with central tumors. Specifically; central location implies a tumor inside the zone of the proximal bronchial tree defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi\n* Evidence of regional or distant metastases after appropriate staging studies.\n* Synchronous primary NSCLC.\n* Those with prior malignancy in the past 2 years other than non-melanomatous skin cancer or in situ cancer or thyroid cancer.\n* Previous lung or mediastinal radiotherapy.\n* Plans for the patient to receive concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol.\n* Patients with active systemic, pulmonary or pericardial infection.\n* Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.",{"count":271,"type":20},[52],"This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.",[436],"Lung Cancer",{"date":419,"type":33},{"date":439,"type":33},"2018-12-15",{"date":441,"type":20},"2034-11-15",{"name":39,"class":40},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":41},"100458358","living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases-100458358","NCT05248581","Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases","Liver Transplantation From Living Donors For Treatment Of Non-Resectable Colorectal Carcinoma Liver Metastases: A Registry Study","Inclusion Criteria:\n\n* Age ≥ 18\n* Non-amenable to curative hepatic resection as defined by FLR \\\u003C30%\n* Histologically confirmed adenocarcinoma of the colon or rectum\n* Candidate for LDLT for colorectal liver metastasis per the University of Rochester liver transplant program\n\nExclusion Criteria:\n\n* Not a candidate of the LDLT liver transplant protocol for treatment of colorectal liver metastasis.\n* Unwilling to consent",{"count":7,"type":20},"The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data\u002Foutcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation.",[453],"Colorectal Cancer Metastatic",[455,456,457],"liver transplantation","living donor","unresectable colorectal liver metastases","2026-07-16",{"date":419,"type":33},{"date":461,"type":33},"2019-08-16",{"date":463,"type":20},"2027-08-01",{"name":39,"class":40},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":21,"phases":474,"briefSummary":475,"conditions":476,"keywords":479,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":41},"100474338","digital-cbt-for-insomnia-and-depression-100474338","NCT05456607","Digital CBT for Insomnia and Depression","Optimizing Digital Behavioral Treatment for Co-occurring Insomnia and Depression","Inclusion Criteria:\n\n* English-speaking\n* U.S. Military Veterans\n* endorse depression (Patient Health Questionnaire-depression score \\> 10)\n* endorse insomnia (Insomnia Severity Index score \\> 10).\n\nExclusion Criteria are limited in accordance with real world effectiveness trials, but will include:\n\n* pregnancy\n* history of bipolar disorder\n* history of psychosis\n* current use of anti-psychotic medications or mood stabilizers (e.g., lithium)\n* current suicidal ideation with active intent",{"count":473,"type":20},1200,[52],"This study has two primary objectives, each of which addresses critical clinical and research gaps for individuals who have co-occurring insomnia and depression. The first objective is to address whether sequential treatment of insomnia and depression is superior to a single treatment for either depression or for insomnia, and if so, which treatment sequence is optimal. The second objective is to determine if there are heterogeneity of treatment effects; that is, variation in which interventions are best for which individuals, and if so, to develop and individualized intervention rule to better match individuals with the treatment that is most likely to lead to the best outcomes. A large randomized trial will be conducted to meet these objectives.",[477,478],"Depression","Insomnia",[480,481,482,483],"cognitive behavioral therapy","digital intervention","depression","insomnia","2026-07-13",{"date":324,"type":33},{"date":487,"type":33},"2023-05-01",{"date":489,"type":20},"2027-09-18",{"name":39,"class":40},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":48,"minAge":219,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":21,"phases":501,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":41},"100437864","a-randomized-trial-of-a-mobile-health-exercise-intervention-for-older-adults-with-myeloid-neoplasms-100437864","NCT04981821","A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms","A Pilot Randomized Trial of a Mobile Health Exercise Intervention for Older Patients With Myeloid Neoplasms","GO-EXCAP2","Inclusion Criteria:\n\n* Age ≥60 years (conventional definition of older age in clinical trials of MN)\n* Have a diagnosis of MN\n* Planned for or receiving outpatient cancer-directed treatments (participants receiving consolidative or maintenance outpatient therapies after induction chemotherapy are allowed to enroll)\n* English speaking\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* No medical contraindications for exercise per oncologist\n* Able to walk 4 meters as part of Short Physical Performance Battery measured walk (with or without assistive device)\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Physical, psychological, or social impairments that would interfere with subject's ability to participate in the study or participate in the intervention, as determined by the PI or the treating team",{"count":500,"type":20},170,[52],"This is a phase 2 randomized controlled trial (RCT) to assess the preliminary efficacy of the a mobile health exercise intervention (GO-EXCAP) versus a chemotherapy education control in 100 older patients with MN receiving outpatient chemotherapy on physical function and patient-reported outcomes (fatigue, mood, and quality of life). We will also explore the effect of the intervention on TNFα and related cytokine gene promoter methylation and their gene and protein expression.",[504,505],"Cancer","Myeloid Neoplasm",[507,505,508],"mobile health exercise intervention","GO-EXCAP",{"date":324,"type":33},{"date":511,"type":33},"2022-01-03",{"date":513,"type":20},"2027-12-31",{"name":39,"class":40},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":268,"sex":48,"minAge":522,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":525,"conditions":526,"keywords":529,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":41},"100375572","skin-microbial-ecology-in-atopic-dermatitis-100375572","NCT04170244","Skin Microbial Ecology in Atopic Dermatitis","Longitudinal \"Real-World\" Changes in Skin Microbial Ecology in Atopic Dermatitis (AD) and Psoriasis (PS) Patients","Inclusion Criteria:\n\n* ≥13 to 65 years of age (inclusive) for PS, ≥13 for AD and NA, male or female\n* Optional Bx sub study - only adults (18-65 yrs; inclusive only)\n* Able to understand protocol and give consent\n* Able to keep clinic\u002Fstudy appointments and comply with study related procedures\n* Must be able to read, speak, and understand English\n* Chronic AD, according to the American Academy of Dermatology (AAD) Consensus Criteria (Eichenfield 2014), that has been present for at least 1 year before the enrollment visit\n* Chronic PS, according to the AAD Consensus Criteria (Menter et al 2008 (section 1)), that has been present for at least 1 year before the enrollment visit.\n* AD subjects: have active lesions on upper extremities, lower extremities, or trunk and a total disease severity of high moderate-to-severe (EASI ≥12)\n* PS subjects: have active lesions on upper extremities, lower extremities, or trunk and a total disease severity of high moderate-to-severe (PASI ≥7)\n\nExclusion Criteria:\n\n* Unwilling and\u002For unable to complete informed consent process\n* \\\u003C13 or \\> 65 years of age for PS, \\>13 for AD and NA\n* AD subjects: disease without upper extremity, lower extremity, or trunk lesions\n* AD subjects: total disease severity less than moderate (EASI \\\u003C12), depending on enrollment\n* PS subjects: disease without upper extremity, lower extremity, or trunk lesions\n* PS subjects: total disease severity less than moderate (PASI \\\u003C7), depending on enrollment\n* Control subjects: diagnosed with an inflammatory skin disease\n* Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the individual's participation in the study (Ex: HIV infection, autoimmune disease, severe heart failure, Hx of malignancy (other than in situ cervical cancer or basosquamous skin cancer), etc.)\n* Recent bacterial, fungal, or viral infection requiring systemic therapies (PO, IV or IM) within the last month.\n* Subjects with a history of serious life-threatening reaction to tape or adhesives may be enrolled but cannot undergo Tape stripping procedure and will therefore only have a baseline TEWL measurement.\n* (For Skin biopsy substudy only) - Subjects with history of keloid formation or allergy to lidocaine.","13 Years",{"count":524,"type":20},240,"Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \\[AD\\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several commensal bacteria) change as a consequence of standard of care treatment in the URMC dermatology clinics. Other assays and biospecimens will also be collected to address a number of questions.",[527,528,275],"Atopic Dermatitis","Psoriasis",[530],"staphylococcus, microbiome, atopic dermatitis, cutibacterium","2026-07-12",{"date":533,"type":33},"2026-07-14",{"date":535,"type":33},"2019-04-17",{"date":537,"type":20},"2027-04-01",{"name":39,"class":40},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":21,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":560},"100441903","phase-4-the-pivatal-study--study-of-ventricular-arrhythmia-vta-ablation-in-left-ventricular-assist-device-lvad-patients-100441903","NCT05034432","The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients","Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)","PIVATAL","Inclusion Criteria:\n\n* Age \\> 18 years\n* Presence of advanced cardiomyopathy (of all INTERMACS classification) and eligible for LVAD implant per the decision of the Heart Failure clinical team\n* Implanted cardioverter defibrillator (ICD) any time in past with remote monitoring or planned to undergo ICD (or ICM as an alternative, if an ICD cannot be implanted for a clinical reason) implant within the index hospitalization for LVAD implant\n* History of treated or monitored sustained (i.e., \\>30 seconds in duration ) VT or VF episode within the past 5 years.\n\nExclusion Criteria:\n\n* Past successful VTA ablation without recurrent VTA prior to LVAD implant (Patients who continue to experience VTA post ablation and pre LVAD implant qualify to be enrolled)\n* Participation in other clinical trials (observational registries are allowed with approval)\n* Unable or unwilling to provide informed consent",{"count":271,"type":20},[23],"To investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery",[551,552],"Arrythmia","Cardiomyopathies","2026-07-10",{"date":533,"type":33},{"date":556,"type":33},"2022-05-27",{"date":558,"type":20},"2027-06-30",{"name":39,"class":40},19,{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":48,"minAge":70,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":21,"phases":571,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":41},"100623199","a-pilot-randomized-controlled-trial-of-a-social-network-intervention-100623199","NCT07393529","A Pilot Randomized Controlled Trial of a Social Network Intervention","A Pilot Randomized Controlled Trial of a Social Network Intervention for Older Patients With Cancer","SONATA 2","Patients\n\nInclusion criteria:\n\n* Age ≥65 years\n* A diagnosis of advanced or likely incurable cancer, as determined by the primary oncologist\n* Able to speak English\n* Able to provide informed consent\n\nExclusion criteria:\n\n* Any psychiatric or cognitive impairments interfering with participation as determined by the oncology team\n* Unwilling to complete study procedures\n\nSocial Network Members (if available, for intervention arm only)\n\nInclusion criteria:\n\n* Age ≥18 years\n* Identified as an SN member by the patient in the intervention arm\n* Able to speak English\n* Able to provide informed consent\n\nExclusion criteria:\n\n• Unwilling to complete study procedures",{"count":570,"type":20},70,[52],"This is a pilot randomized controlled trial to assess the feasibility, acceptability, appropriateness, and structure of the SONATA intervention. In addition, it will assess the preliminary efficacy of SONATA compared to enhanced usual care among 70 older adults with advanced cancer.",[574,575,576],"Advanced Cancer","Older Adults (65 Years and Older)","Social Networks",[578,579],"geriatric oncology","social networks","2026-07-02",{"date":582,"type":33},"2026-07-07",{"date":584,"type":33},"2026-04-10",{"date":586,"type":20},"2029-03-31",{"name":39,"class":40},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":48,"minAge":70,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":21,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":41},"100622932","exercise-and-cognitive-rehabilitation-interventions-for-older-cancer-survivors-100622932","NCT07390045","Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors","Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors: A Pilot Randomized Controlled Trial","ECO 2","Inclusion criteria:\n\n* Age ≥65 years (from date of consent, confirmed on the electronic medical record)\n* A diagnosis of any cancer\n* Have completed curative intent treatments\n\n  * Patients on endocrine therapies are allowed to enroll\n  * Patients with hematologic malignancies after autologous or allogeneic stem cell transplant are allowed to enroll if they have completed curative-intent treatment\n* Answered \"yes\" to the verbal question \"Do you have concerns about memory or other thinking abilities following your cancer treatment?\"\n* Able to speak English (interventions are available in English only)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3#\n* No medical contraindications to exercise#\n* Able to walk 4 meters#\n* Able to provide informed consent#\n\n  * Confirmed through eligibility confirmation with the patient's oncologist or their designee\n\nExclusion criteria:\n\n* Any physical, psychological, or social impairments that would interfere with a patient's ability to participate in the study as determined by the patient's oncologist or their designee\n* Unwilling to complete study procedures",{"count":315,"type":20},[52],"The objective of this study is to assess the preliminary effects of an integrated exercise and cognitive rehabilitation intervention (ECO), an exercise intervention (EXCAP), and a cognitive rehabilitation intervention (MAAT) as compared to usual care on objective cognition (Trail Making Test).",[504],[578,601,602,603,604],"cancer survivors","exercise","cognitive rehabilitation","cognition",{"date":606,"type":33},"2026-07-06",{"date":608,"type":20},"2026-07-31",{"date":610,"type":20},"2028-03-31",{"name":39,"class":40},""]